Poxel/Sumitomo's Novel Diabetes Therapy Imeglimin Nears Japan Market
A Phase III-Ready Partnering Opportunity For EU/US
Poxel’s potential first-in-class diabetes therapy, imeglimin, could be approved in Japan this year, and a new partner is being sought for the EU and US – events that would transform the outlook for the decade-old Merck Serono spin-out.
You may also be interested in...
A version of the diabetes drug intended to reduce PPAR gamma activation shows hoped for benefits and safety in a Phase II study. Poxel will now choose to advance one of two mid-stage NASH candidates.
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
Japan's latest batch of product approvals includes the country's second therapy for SMA and the first nod globally for a novel antidiabetic.